Navigation Links
Catching cancer early by chasing it
Date:8/1/2013

WASHINGTON D.C. August 1, 2013 -- Reaching a clinic in time to receive an early diagnosis for cancer -- when the disease is most treatable -- is a global problem. And now a team of Chinese researchers proposes a global solution: have a user-friendly diagnostic device travel to the patient, anywhere in the world.

As described in the journal Biomicrofluidics, which is produced by AIP Publishing, a team led by Gang Li, Ph.D., from Shanghai Institute of Microsystem and Information Technology at the Chinese Academy of Sciences, is developing a portable device for point-of-care diagnostic testing to detect cancer at its earliest stages. It identifies cancer biomarkers, which are biological indicators of the disease that often circulate in the blood prior to the appearance of symptoms.

The new device is based on microfluidics -- a technology that has rapidly expanded over the past decade and involves miniature devices that tightly control and manipulate tiny amounts of fluids for analysis through channels at the micro- and nano-scales.

Researchers value microfluidic technology for its low cost, speedy analysis of fluids and non-turbulent flows, and small footprint, Li said.

Inexpensive and easy-to-use, the Li team's device eliminates the need for an external power supply by relying on a specially fabricated pump to sample reagents and move fluids through microchannels.

"Our device is well suited to helping early diagnosis in resource-limited settings where no mechanical pumps or power sources are readily available because it is portable, affordable, sensitive, and specific, and delivered by technology with a user-friendly analytical platform," Li said.

He noted that the specialized pump can be prepared in advance and stored in an air-tight package. To further suit it to low-tech, rural or field conditions of use, the device allows users to read results with the naked eye or a digital camera, eliminating the need for any expensive and complicated equipment.


'/>"/>

Contact: Jason Socrates Bardi
jbardi@aip.org
240-535-4954
American Institute of Physics
Source:Eurekalert

Related biology news :

1. Catching up with catch shares
2. Forensic tools for catching poachers
3. UPCI researchers target cell sleep to lower chances of cancer recurrence
4. Study highlights possible new approach to prostate cancer treatment
5. Scientists discover a molecular switch in cancers of the testis and ovary
6. New 3-D colonoscopy eases detection of precancerous lesions
7. The naked mole-rats secret to staying cancer free
8. Study finds missing piece of pediatric cancer puzzle
9. Alternative target for breast cancer drugs
10. LSUHSC researcher awarded NCI grant to study link between chronic inflammation and cancer
11. Ovarian cancer metastases influenced by factors in target tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: